Fifth Third Bancorp Purchases 24,557 Shares of Boston Scientific Corporation $BSX

Key Points

• Fifth Third Bancorp increased its stake in Boston Scientific Corporation by 9.0%, acquiring 24,557 shares during the second quarter, bringing its total holdings to 296,046 shares, valued at approximately $31.8 million.
• Several institutional investors have also significantly increased their positions in Boston Scientific, contributing to 89.07% of the company's stock being owned by institutional and hedge funds.
• Boston Scientific reported a 22.8% year-over-year revenue increase for the last quarter, with earnings per share surpassing estimates at $0.75, as well as setting guidance for Q3 2025.

Fifth Third Bancorp boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 9.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,046 shares of the medical equipment provider's stock after buying an additional 24,557 shares during the quarter. Fifth Third Bancorp's holdings in Boston Scientific were worth $31,798,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider's stock worth $3,167,000 after purchasing an additional 3,932 shares during the last quarter. NS Partners Ltd raised its position in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock worth $37,143,000 after acquiring an additional 5,704 shares during the last quarter. Bank of New Hampshire lifted its stake in shares of Boston Scientific by 552.0% in the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider's stock worth $2,119,000 after acquiring an additional 16,699 shares during the period. MRA Advisory Group bought a new stake in Boston Scientific in the second quarter valued at approximately $273,000. Finally, Neville Rodie & Shaw Inc. increased its position in Boston Scientific by 95.9% during the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider's stock valued at $4,883,000 after purchasing an additional 22,255 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BSX. Leerink Partners assumed coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Truist Financial lifted their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and upped their target price for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Finally, Wells Fargo & Company increased their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Boston Scientific presently has an average rating of "Buy" and an average target price of $118.17.

Boston Scientific Trading Up 0.3%

BSX opened at $98.02 on Thursday. The firm has a market capitalization of $145.24 billion, a PE ratio of 58.35, a P/E/G ratio of 2.35 and a beta of 0.65. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The company's 50-day moving average is $104.03 and its 200 day moving average is $102.03. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,214 shares of company stock worth $18,397,457. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.